How Does Ozempic Actually Work? The Diabetes Drug Behind the Headlines

What is Ozempic actually approved to treat?

Ozempic first reached the market in December 2017, approved only to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. That's still its core job today. In January 2020, the approval expanded to cover reducing the risk of major cardiovascular events — heart attack, stroke, cardiovascular death — in adults with type 2 diabetes who already have established heart disease. A higher 2mg weekly dose followed in 2022, for people whose blood sugar wasn't fully controlled on the lower doses.

The newest approval is the one fewest people have heard of. In January 2025, the FDA cleared Ozempic to reduce the risk of worsening kidney function, kidney failure, and cardiovascular death in adults with both type 2 diabetes and chronic kidney disease — the first GLP-1 medication approved specifically for that combination. Weight loss has never appeared on that approval list, however common it's become as the reason people ask for the prescription.

So what does Ozempic actually do in the body?

The active ingredient is semaglutide, a lab-made copy of GLP-1 (glucagon-like peptide-1) — a hormone your gut already releases in small amounts after you eat. Natural GLP-1 breaks down within minutes. Semaglutide is engineered to persist for roughly a week per dose, turning a brief after-meal signal into one your body responds to continuously.

• Prompts your pancreas to release insulin, but only when blood sugar is already elevated — part of why it doesn't tend to cause the sugar crashes some older diabetes medications do
• Lowers how much glucagon, a sugar-raising hormone, your liver receives — so less stored sugar gets released into your blood between meals
• Slows how quickly food leaves your stomach, which extends the feeling of fullness after eating
• Acts on appetite centers in the hypothalamus and brainstem, quieting hunger signals — the effect behind the weight loss almost everyone associates with the name now

That last effect is a side effect of the underlying biology, not a separate function bolted on. The same receptor that manages blood sugar also sits in appetite-regulating parts of the brain, which is exactly why a diabetes drug started producing weight loss substantial enough that an entire second medication — Wegovy — was built and approved around it.

If it's not approved for weight loss, why do doctors prescribe it for that anyway?

Off-label prescribing is legal and routine in medicine, and it happens constantly with Ozempic. A doctor can prescribe an FDA-approved drug for a use outside its specific approval when clinical judgment and evidence support it — and semaglutide's weight-loss evidence is substantial, borrowed from Wegovy's own dedicated trials, since the molecule is identical. What actually differs between the two products is the dose ceiling and the paperwork: Ozempic tops out at 2mg weekly, while Wegovy climbs to 2.4mg standard, with a 7.2mg step-up option for people who've plateaued, and only Wegovy carries the FDA's dedicated weight-management approval.

This is also where insurance coverage gets complicated. A plan that covers Ozempic for a documented type 2 diabetes diagnosis often won't cover it — or covers it only after an appeal — for weight loss alone, because that use sits outside the approved label. What Ozempic actually costs walks through how that plays out across insurance, cash pay, and compounded versions.

Does perimenopause change any of this?

The receptor biology itself doesn't shift with reproductive stage — semaglutide binds the same GLP-1 receptors at 46 as it would at 30. What changes is the body it's acting on. Declining, fluctuating estrogen during perimenopause is linked to rising insulin resistance, a shift in fat storage toward the abdomen, and a drop in resting metabolic rate as muscle mass declines — changes that can move someone's blood sugar or weight into a range where a GLP-1 medication becomes clinically relevant for the first time in her 40s, independent of anything she's doing differently.

That's part of why this conversation looks different for women navigating perimenopause than it did for the general population the original diabetes trials were built around. Our guide to GLP-1 medications and menopause goes deeper into how that overlap plays out, including where hormone therapy fits alongside a GLP-1 rather than instead of one.

Can you get Ozempic as a pill now, or is it only the injection?

It was injection-only from 2017 until May 4, 2026, when Novo Nordisk launched an oral Ozempic tablet nationwide — a next-generation, more absorbable semaglutide formulation taken once daily on an empty stomach, in 1.5mg, 4mg, and 9mg strengths. It's effectively the successor to Rybelsus, an older oral semaglutide product the company is phasing out under the Ozempic name. Same active ingredient, same underlying mechanism, different route into your body — a pill has to survive stomach acid to work, which is why it's formulated and dosed differently than the weekly injection.

What's the safety warning about — and does it apply differently for weight loss?

Ozempic carries a boxed warning, the FDA's strongest safety label, for thyroid C-cell tumors seen in rodent studies; it hasn't been confirmed in humans, but it's serious enough that the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. That warning is tied to the mechanism itself, so it's identical whether the prescription is for diabetes or off-label for weight — the reason for taking it doesn't change what the molecule does. What Ozempic actually does to your body week to week covers the far more common, non-boxed effects, like early nausea, separately from this rarer structural warning.

How does this compare to Wegovy, Mounjaro, or the other names you keep hearing?

Ozempic and Wegovy are the same molecule, semaglutide, at different doses with different FDA approvals — Ozempic for diabetes and its related cardiovascular and kidney risks, Wegovy specifically for weight. How Wegovy's version of this mechanism works covers that side in more depth, including its own newer approvals. Mounjaro and Zepbound are a different molecule entirely, tirzepatide, which acts on two gut-hormone receptors instead of one and tends to produce larger average weight loss in head-to-head trials. None of that changes what Ozempic itself is built to do — it simply isn't the only option in the conversation anymore.